Support
: 888-992-3836
|
Newswire
|
Home
|
Log in
Boards
Stocks
Commodities
Forex
Cryptocurrency
The Lounge
Hot!
Breakout Boards
Follow Feed
iHub My Stocks Activity
Ticker Buzz Cloud
Most Read
Most Posted
Most Followed Members
Recent News
Active Boards
Site Stats
New Boards
Cannabis Stocks
Top PlusOneCoin Posters
Tools
Data Tools >
Charts
Trader Alerts
Trades
Portfolio
Top Lists
Price & News Alerts
Commodities
Markets in 3D
NewsWire
More Tools >
Newsletters
My Image Gallery
Advanced Search
Videos
All News
Stock Screener
News Filter
Live Charts
Live News
Live Desktop
Forex Prices
Commodities
ETF Center
Educational Channel
Personal Finance Q&A
Follow Feed
Crypto
Cryptocurrency
PlusOneCoin Learn
Streamer
Level 2
Home
>
Boards
>
US OTC
>
Biotechs
>
Oxford BioMedica PLC (OXBDF)
Add OXBDF Price Alert
Hide Sticky
Hide Intro
Moderator:
Search This Board:
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003+
Last Post:
4/20/2018 4:51:02 AM
-
Followers:
6
- Board type:
Free
- Posts Today:
1
Oxford BioMedica PLC (OXBDF)
Trades In UK as (OXB.L)
Company website
UK company traded on grey's in US
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom -
Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001
Oxford BioMedica plc
, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Management
Partnerships
Financial Reports:
http://www.oxfordbiomedica.co.uk/financial-reports/
Investor Contacts:
http://www.oxfordbiomedica.co.uk/investor-contacts/
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.
Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp
OXBDF
Current Price
Volume:
Bid
Ask
Day's Range
OXBDF Detailed Quote
1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y
Post New Msg
Follow Board
My Stocks (0)
Hide Intro
View Posters
OXBDF Poststream
Bans (0)
Hide Quote
Filter Disabled
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
Post
Subject
#616
0
In April we announced an agreement to acquire
marcusl2
04/20/18 04:51:02 AM
#615
0
https://seekingalpha.com/article/4164128-novartis-ag-2018-q1-results-earnings-ca
marcusl2
04/19/18 04:35:08 PM
#614
0
More work and royalties for OXB
marcusl2
04/19/18 04:31:03 PM
#613
0
Kudos! On the grey sheet with a
JUST 10-11-12
04/16/18 10:53:40 PM
#612
0
Could it be that Novartis is negotiating to
georgejjl
04/16/18 09:42:28 PM
#611
0
OXBDF up 117.88% today Monday April 16, 2018
georgejjl
04/16/18 08:11:20 PM
#610
0
Vulpes buy
marcusl2
04/11/18 03:44:10 PM
#609
0
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antige
georgejjl
04/10/18 08:33:18 PM
#608
0
Novartis bets big on gene therapy with $8.7
georgejjl
04/09/18 07:59:56 PM
#607
0
Advances in Cancer Immunotherapy for Lymphoma
georgejjl
04/06/18 01:46:21 PM
#606
0
Great stuff thanks George. A deal for it
marcusl2
04/04/18 05:11:27 AM
#605
0
Click and read the pdf file
georgejjl
04/03/18 07:50:54 PM
#604
0
Preclinical Assessment of CAR T-Cell Therapy Targeting the
georgejjl
04/03/18 07:39:15 PM
#603
0
The 5T4 oncofetal glycoprotein does not act as
georgejjl
04/03/18 07:35:12 PM
#602
0
The breast cancer antigen 5T4 interacts with Rab11,
georgejjl
04/03/18 07:32:27 PM
#601
0
more than 2 companies very interested in Prosavin
marcusl2
03/20/18 04:13:27 PM
#600
0
http://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-do
marcusl2
03/20/18 05:04:28 AM
#599
0
14:05 Advances in CAR-T Therapy for Chronic Lymphocytic
marcusl2
03/19/18 03:56:53 PM
#598
0
HTTPS://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358667/ In Brief
marcusl2
03/19/18 03:55:25 PM
#597
0
09:35 Design of a Highly Efficacious CAR Targeting
marcusl2
03/19/18 03:55:00 PM
#596
0
Carl June "Cancer therapy poised for rapid advances,
marcusl2
03/14/18 11:51:37 AM
#595
0
Marcus.. Can you update TOTAL OS on here?
Chaka
03/12/18 02:09:21 PM
#594
0
M&G is an investment manager in the UK
marcusl2
03/12/18 06:10:56 AM
#593
0
Foret UK PPS ATM.
Chaka
03/11/18 03:29:51 PM
#592
0
Oxford Biomedica announces placing to inject £20.5m for expansion
georgejjl
03/09/18 08:03:48 PM
#591
0
Optogenetic Tractography for anatomo-functional characterization of cortico-subc
georgejjl
03/09/18 06:09:57 PM
#590
0
The Placing has been supported by a range
marcusl2
03/09/18 04:49:08 PM
#589
0
That was a surprise at 3pm!
marcusl2
03/09/18 04:48:36 PM
#588
0
University of Pennsylvania, told HemOnc Today. “I would
marcusl2
03/09/18 04:47:52 PM
#587
0
Oxford BioMedica PLC (LON:OXB): Is Breakeven Near?
georgejjl
03/08/18 07:44:55 AM
#586
0
Gene therapy was a boy’s last chance to
marcusl2
03/05/18 09:09:43 AM
#585
0
http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-docume
marcusl2
02/28/18 04:30:28 AM
#584
0
So I would guess that our 2nd undisclosed
marcusl2
02/25/18 05:10:29 AM
#583
0
So in Haemophilia Lenti should be better than
marcusl2
02/23/18 05:42:17 PM
#582
0
Helen Maunder, PhD
marcusl2
02/23/18 10:37:17 AM
#581
0
From LSE. Nice to hear
marcusl2
02/21/18 06:30:24 AM
#580
0
Safety and efficacy of OXB-202, a Genetically-Engineered Tissue
georgejjl
02/19/18 11:52:36 PM
#579
0
Celgene and Bluebird Bio
georgejjl
02/19/18 07:57:27 AM
#578
0
https://endpts.com/bioverativ-inks-100m-gene-therapy-deal-with-oxford-biomedica/
marcusl2
02/18/18 04:33:20 AM
#577
0
He reckons Novartis` Cart BCMA has cured him
marcusl2
02/16/18 05:58:40 PM
#576
0
2018 is predicted to be profitable for Oxford BioMedica
georgejjl
02/16/18 09:06:33 AM
#575
0
Oxford BioMedica
marcusl2
02/16/18 04:22:52 AM
#574
0
HTTPS://www.thetimes.co.uk/article/oxford-biomedica-clinches-second-gene-therapy
marcusl2
02/16/18 04:21:59 AM
#573
0
$100 million here and $100 million there can
georgejjl
02/15/18 08:49:36 PM
#572
0
Expect more from the Novartis/Oxford BioMedica collaboration
georgejjl
02/15/18 07:59:03 PM
#571
0
Under the terms of the agreement, Oxford BioMedica
marcusl2
02/15/18 04:33:31 AM
#570
0
Prosavin http://www.acnr.co.uk/wp-content/uploads/2014/08/ja-sheila-roy.gif Partici
georgejjl
02/14/18 08:46:40 PM
#569
0
HTTPS://www.youtube.com/watch?v=Dh_helDPpIg So the Chinese study treated earl
marcusl2
02/13/18 08:08:05 AM
#568
0
Mantle Cell Lymphoma
marcusl2
02/09/18 06:01:26 AM
#567
0
CART 5T4 combined with IL-12 plus doxorubicinn could
georgejjl
02/01/18 07:08:29 PM
Post
Subject
Post New Msg
Follow Board
My Stocks (0)
Hide Intro
View Posters
OXBDF Poststream
Bans (0)
Hide Quote
Filter Disabled
Balance Available:
0
© 2018 InvestorsHub.com, Inc.